Dexamethasone augmentation in treatment-resistant depression

Acta Psychiatr Scand. 1997 Jan;95(1):58-61. doi: 10.1111/j.1600-0447.1997.tb00374.x.

Abstract

A total of 10 patients who fulfilled DSM-III-R criteria for major depression were recruited to the study, each of whom had failed to respond to a 6-week course of treatment with either sertraline or fluoxetine. Each subject had baseline serum cortisol measurements together with a Hamilton depression (HAMD) score. All patients were started on dexamethasone (3 mg daily) for 4 days, while remaining on their antidepressant treatment. Further Hamilton ratings were made on days 5 and 21. Six patients showed a significant improvement, whilst two showed a minimal response. A good clinical response was associated with a high baseline cortisol level.

MeSH terms

  • 1-Naphthylamine / administration & dosage
  • 1-Naphthylamine / analogs & derivatives
  • Adult
  • Antidepressive Agents, Second-Generation / administration & dosage*
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / psychology
  • Dexamethasone / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Fluoxetine / administration & dosage
  • Humans
  • Hydrocortisone / blood
  • Hypothalamo-Hypophyseal System / drug effects
  • Male
  • Middle Aged
  • Personality Inventory
  • Pituitary-Adrenal System / drug effects
  • Selective Serotonin Reuptake Inhibitors / administration & dosage*
  • Sertraline
  • Treatment Outcome

Substances

  • Antidepressive Agents, Second-Generation
  • Serotonin Uptake Inhibitors
  • Fluoxetine
  • Dexamethasone
  • 1-Naphthylamine
  • Sertraline
  • Hydrocortisone